ProQR Therapeutics (PRQR) Total Liabilities (2012 - 2026)
ProQR Therapeutics (PRQR) posted Total Liabilities of $71.9 million for Q1 2026, down 2.51% sequentially from $73.8 million in Q4 2025, and down 6.01% YoY from $76.5 million in Q1 2025.
ProQR Therapeutics (PRQR) Total Liabilities (2012 - 2026) Analysis & Trends
ProQR Therapeutics has reported Total Liabilities for 15 years, with the latest figure at $71.9 million in Q1 2026.
- Quarterly Total Liabilities fell 6.01% year-over-year to $71.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.9 million (down 6.01% YoY) and the FY2025 annual result came in at $73.8 million, down 13.04% from the prior year.
- Total Liabilities retreated to $71.9 million in Q1 2026 per PRQR's latest filing, from $73.8 million in the prior quarter.
- Over five years, Total Liabilities peaked at $106.8 million in Q4 2022 and troughed at $57.7 million in Q3 2022.
- A 5-year average of $89.8 million and a median of $91.7 million in 2024 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 82.06% in 2022, down 99.8% in 2022.
- Over 5 years, Total Liabilities stood at $106.8 million in 2022, then slipped by 2.75% to $103.8 million in 2023, then dropped by 18.28% to $84.8 million in 2024, then declined by 13.04% to $73.8 million in 2025, then retreated by 2.51% to $71.9 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $71.9 million, $73.8 million, and $78.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 71.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71.93 Mn |
| Dec 31, 2025 | 73.78 Mn |
| Sep 30, 2025 | 78.65 Mn |
| Jun 30, 2025 | 79.86 Mn |
| Mar 31, 2025 | 76.53 Mn |
| Dec 31, 2024 | 84.84 Mn |
| Sep 30, 2024 | 89.91 Mn |
| Jun 30, 2024 | 91.75 Mn |
| Mar 31, 2024 | 96.75 Mn |
| Dec 31, 2023 | 103.82 Mn |
| Sep 30, 2023 | 104.17 Mn |
| Jun 30, 2023 | 105.07 Mn |
| Mar 31, 2023 | 106.59 Mn |
| Dec 31, 2022 | 106.76 Mn |
| Sep 30, 2022 | 57.67 Mn |
| Jun 30, 2022 | 98.25 Mn |
| Mar 31, 2022 | 101.03 Mn |
| Dec 31, 2021 | 110.22 Mn |
| Sep 30, 2021 | 79.38 Mn |
| Jun 30, 2021 | 53.97 Mn |